SCHEMBL10081089

SCHEMBL10081089

Cc1cncc(-c2ccc3nc(Nc4ccncc4)sc3c2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 9/20 0.64
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
KDM4E B2RXH2 1/20 0.49
PIK3CA P42336 4/20 0.46
ABL1 P00519 4/20 0.46
ROCK2 O75116 1/20 0.46
MAP4K4 O95819 1/20 0.46
PRKCG P05129 1/20 0.46
LYN P07948 1/20 0.46
PRKACA P17612 1/20 0.46
RPS6KB1 P23443 1/20 0.46
AKT1 P31749 1/20 0.46
FLT3 P36888 1/20 0.46
CSNK1D P48730 1/20 0.46
CLK2 P49760 1/20 0.46
IRAK1 P51617 1/20 0.46
PRKX P51817 1/20 0.46
NEK4 P51957 1/20 0.46
PRKCD Q05655 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10081159 0.90 PIK3CG (0.64) PIK3CGMEN1KMT2APIK3CAABL1
SCHEMBL10081088 0.87 PIK3CG (0.60) PIK3CGMEN1KMT2APIK3CAABL1
SCHEMBL10081160 0.85 PIK3CG (0.60) PIK3CGMEN1KMT2APIK3CAABL1
SCHEMBL10081084 0.84 PIK3CG (0.59) PIK3CGPIK3CAABL1KITPDGFRA
SCHEMBL10081092 0.83 PIK3CG (0.58) PIK3CGMEN1KMT2APIK3CAABL1
SCHEMBL10081090 0.83 PIK3CG (0.58) PIK3CGMEN1KMT2APIK3CAABL1
SCHEMBL10085281 0.82 PIK3CD (0.59) PIK3CGMEN1KMT2AKDM4EPIK3CA
SCHEMBL10081081 0.82 PIK3CG (0.60) PIK3CGMEN1KMT2APIK3CAABL1
SCHEMBL10081094 0.81 PIK3CG (0.58) PIK3CGPIK3CAABL1KITPDGFRA
SCHEMBL10081095 0.80 PIK3CG (0.55) PIK3CGMEN1KMT2APIK3CAABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268999-B2 Tri-cyclic pyrazolopyridine kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-18 US disclosed
US-20120053187-A1 TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053187-A1 TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS PIK3CA, PIK3CD, PIK3CG PIK3CG 3/4885MEN1 3841/4885KMT2A 2972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.